OmniAb, Inc. $OABI Shares Newly Acquired by Cornerstone Capital Inc.

Cornerstone Capital Inc. purchased a new stake in OmniAb, Inc. (NASDAQ:OABI – Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 107,986 shares of the company’s stock, valued at approximately $536,000. Cornerstone Capital Inc. owned approximately 0.07% of OmniAb at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in OABI. Whitefort Capital Management LP acquired a new position in OmniAb during the 2nd quarter worth approximately $25,211,699. BlackRock Inc. bought a new position in OmniAb in the 2nd quarter valued at approximately $21,888,000. Rice Hall James & Associates LLC bought a new position in OmniAb in the 2nd quarter valued at approximately $6,422,000. State Street Corp boosted its position in OmniAb by 3.2% in the second quarter. State Street Corp now owns 2,133,549 shares of the company’s stock valued at $5,249,000 after buying an additional 66,406 shares in the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in OmniAb in the second quarter valued at approximately $2,331,000. 72.08% of the stock is currently owned by institutional investors and hedge funds.

OmniAb Trading Down 0.4%

NASDAQ:OABI opened at $4.89 on Tuesday. The stock has a market cap of $713.26 million, a P/E ratio of -14.38 and a beta of 0.60. The stock’s 50-day moving average is $4.75 and its 200-day moving average is $2.88. OmniAb, Inc. has a 1-year low of $1.35 and a 1-year high of $5.45.

OmniAb (NASDAQ:OABI – Get Free Report) last issued its quarterly earnings data on Friday, October 30th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. OmniAb had a negative net margin of 108.11% and a negative return on equity of 16.74%. The business had revenue of $3.99 million during the quarter, compared to analyst estimates of $3.49 million. As a group, equities analysts forecast that OmniAb, Inc. will post -0.34 EPS for the current year.

Analyst Ratings Changes

OABI has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of OmniAb in a research note on Monday, August 17th. Leerink Partners increased their price target on OmniAb from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Wednesday, October 7th. Finally, Weiss Ratings raised OmniAb from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 20th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.50.

Read Our Latest Research Report on OABI

OmniAb Company Profile

(Free Report)

OmniAb, Inc. is a biotechnology company that develops antibody discovery technologies for use in creating therapeutic medicines. It works with pharmaceutical and biotechnology companies to identify and advance antibody candidates for potential drug development. Its platform includes genetically engineered animals that can produce antibodies with human characteristics, along with related discovery and screening technologies. These tools are designed to help partners find antibodies for a range of therapeutic targets and applications.

Further Reading

Institutional Ownership by Quarter for OmniAb (NASDAQ:OABI)

Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.